<DOC>
	<DOCNO>NCT00460382</DOCNO>
	<brief_summary>The purpose study look safety efficacy combination 3 new antiretroviral drug : darunavir , etravirine MK-0518 ( raltegravir ) patient multi-resistant virus limit treatment option . An optimized background regimen may include nucleoside reverse transcriptase inhibitor ( NRTIs ) enfuvirtide add , possible , combination . Patients undergo treatment 48 week virological efficacy evaluate week 24 .</brief_summary>
	<brief_title>Clinical Trial Assess Efficacy Darunavir/Ritonavir ( DRV/r ) , Etravirine ( ETV ) Raltegravir ( MK-0518 ) HIV Patients With Resistant Viruses</brief_title>
	<detailed_description>Methods : A phase II pilot , prospective , open label , single arm multicentric clinical trial assess darunavir/ritonavir , etravirine MK-0518-containing regimen , possible associate optimized background regimen may include NRTIs enfuvirtide , HIV-1 infect patient fail combination antiretroviral therapy multi-resistant virus . Treatment strategy : Patients receive raltegravir ( MK-0518 ) , darunavir/ritonavir ( TMC114/r ) etravirine ( TMC125 ) possible optimize background therapy . - raltegravir ( MK-0518 ) ( 400 mg x 2/d = one 400 mg pill twice daily ) - darunavir ( 600 mg x 2/d= two 300 mg pill twice daily meal ) - ritonavir ( 100 mg x 2/d = one 100 mg pill twice daily meal ) - etravirine ( 200 mg x 2/d = two 100 mg pill twice daily meal ) - possible optimized background therapy : may include NRTI ( ) enfuvirtide nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) protease inhibitor ( PIs ) . NRTIs choice leave clinician 's discretion . Enfuvirtide highly recommend enfuvirtide-naive patient leave clinician . Main outcome : proportion patient HIV RNA level less 50 copies/ml intent treat analysis W24 . Secondary outcome : proportion patient HIV RNA level less 50 copies/ml week 48 , HIV RNA level less 400 copies/ml week 24 48 ; HIV RNA level evolution baseline week 48 ; HIV proviral DNA 2LTR circle HIV DNA baseline week 48 ; number type resistance mutation case virologic failure occurrence ; CD4 lymphocyte count proportion evolution baseline week 48 ; HIV infection progression ; frequency study regimen modification interruption ; study regimen tolerance ; study regimen adherence ; association study drug ' minimum concentration week 4 virologic success week 24 ; evolution pharmacokinetic parameter study drug week 1 week 4 Pharmacokinetic substudy . Sample size : 103 patient Enrollment period : 24 week Patient 's participation duration : 52 week An extended follow-up ( week 52 week 96 ) add April 2008 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Age : 18 year Documented HIV1 infection . History virological failure NNRTIs ( patient history toxicity nevirapine efavirenz may enrol study ) . On combination antiretroviral therapy least 8 week prior screen visit ( tipranavir , enfuvirtide drug introduce 8 week screen visit ) . Patient naive darunavir , etravirine integrase inhibitor Plasma viral load screen visit 1000 copies/ml , ( CD4 restriction ) . Genotypic resistance test screen visit : Protease inhibitor mutation : equal 3 primary protease inhibitor mutation among : D30N , V32I , L33F , M46I/L , I47A/V , G48V , I50L/V , I54M , L76V , V82A/F/L/T/S , I84V , N88S L90M ( IAS list 2006 ) equal 3 mutation among follow : V11I , V32I , L33F , I47V , I50V , I54L/M , G73S , L76V , I84V et L89V ( virus sensitivity darunavir/ritonavir ) . Reverse transcriptase mutation : equal 3 NRTI mutation ( among IAS list ) equal 3 mutation among : A98G , L100I , K101Q/P/E , K103H/N/S/T , V106A/M , V108I , E138G/K/Q , V179D/E/F/G/I , Y181C/I/V/C/H/L , Y188C/H/L , G190A/C/E/Q/S , P225H , F227C/L , M230I/L , P236L , K238N/T Y318F ( virus sensitivity etravirine ) Non effective barrier contraception woman child bear potential Pregnant woman woman breastfeed Opportunistic infection acute phase Decompensated cirrhosis ( stage B C ChildPugh score ) Malignancy require chemotherapy radiotherapy Contraindicated medication take patient ( list protocol ) Allergy active substance expedient darunavir , etravirine raltegravir . Haemoglobin &lt; 7g/dl , neutrophil cell count &lt; 500/mm3 , platelet &lt; 50,000/mm3 , creatinine clearance &lt; 50 ml/mn , P. alkaline , AST , ALT total bilirubin equal 3 time normal value . Patients receive experimental agent exclusion period participation study applicable screen visit current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>HIV integrase inhibitor</keyword>
	<keyword>etravirine</keyword>
	<keyword>darunavir</keyword>
	<keyword>MK 0518</keyword>
	<keyword>raltegravir</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Antiviral drug resistance</keyword>
</DOC>